Company news

Aquestive Therapeutics, Inc. news in 2024

Aquestive Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

December 18, 2024

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

December 1, 2024

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

November 11, 2024

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 3, 2024

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American Coll...

October 24, 2024

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

October 23, 2024

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8: 00 a.m. ET

October 20, 2024

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

September 26, 2024

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

September 8, 2024

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

August 13, 2024

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

July 24, 2024

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8: 00 a.m. ET

July 22, 2024

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

June 26, 2024

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

June 24, 2024

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

June 17, 2024

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

June 2, 2024

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

May 27, 2024

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

May 8, 2024

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

April 28, 2024

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8: 00 a.m. ET

April 24, 2024

Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

April 11, 2024

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

March 31, 2024

Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

March 24, 2024

Aquestive Therapeutics Announces Proposed Public Offering of Common Stock

March 18, 2024

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock

March 18, 2024

Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting

March 13, 2024

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

March 4, 2024

Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8: 00 a.m. ET

February 20, 2024

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting

February 14, 2024

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference

January 29, 2024

Calls in 2024

Decks in 2024